Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC Phil A.J.

Slides:

Advertisements

Similar presentations

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Advertisements

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Rebecca Muirhead, MBChB, MRCP, Stuart G

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Adequacy of Intraoperative Nodal Staging during Surgical Resection of NSCLC: Influencing Factors and Its Relationship to Survival Tim Edwards, FRACP,

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables Timothy Edwards, Charlene.

Prevention and Management of Bone Metastases in Lung Cancer: A Review

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non–Small Cell Lung Cancer Aritoshi Hattori, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

A Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non- small Cell Lung Cancer Esther Herpel, MD, Thomas Muley, PhD, Thomas.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

ES Lung Cancer Surgery for High Risk Patients

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

It’s All in the “Swerve of the Curve”

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

International Thymic Malignancies Interest Group: A Way Forward

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Lung Cancer in New Zealand: Patterns of Secondary Care and Implications for Survival Wendy Stevens, MBBS, Graham Stevens, MD, FRANZCR, John Kolbe, MBBS,

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Who should decide margin length in pulmonary excision of lung cancer?

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Haval Balata, MBChB, MRCP, Kwun M. Fong, M. B. B. S

Presentation transcript:

Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC Phil A.J. Crosbie, MBChB, MRCP, PhD, Rajesh Shah, M.B.B.S., MS, Piotr Krysiak, Cong Zhou, BSc, PhD, Karen Morris, BSc (Hons), PhD, Jonathan Tugwood, BSc (Hons), PhD, Richard Booton, MBChB, PhD, Fiona Blackhall, BSc (Hons), MBChB (Hons), PhD, Caroline Dive, BPharm, PhD Journal of Thoracic Oncology Volume 11, Issue 10, Pages 1793-1797 (October 2016) DOI: 10.1016/j.jtho.2016.06.017 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Survival in patients after curative-intent surgical resection of NSCLC. (A) Disease-free survival (DFS) and (B) 3-year overall survival (OS) according to pulmonary vein circulating tumor cell (CTC) status. (C) DFS and (D) 3-year OS according to peripheral vein CTC detection. (E) DFS and (F) 3-year OS stratified according to high- and low-risk CTC groups. CMT, circulating tumor microemboli. Journal of Thoracic Oncology 2016 11, 1793-1797DOI: (10.1016/j.jtho.2016.06.017) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions